Forward Looking Statements This presentation contains, in addition to historical information, forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate

Near Term Milestones GR MD 02: IND Dec 2012; Phase I Q1 2013 with results Q3 2013; Phase II results end of 2014. GM CT 01: Phase I/II interim results Dec. 2012. Experienced Management Team and Board Management team has collective experience in multiple biotechnology and large Pharma companies and relevant scientific areas. Can deliver on the program.

Novel class of safe, complex carbohydrate drugs. Strong patent position; Own 100% of commercial rights. Large Market Opportunities NASH and liver fibrosis indications would be first therapies for completely unmet medical needs, representing a multi billion dollar market. Enhanced immune killing of cancer cells is synergistic with many current and experimental therapies, expected to be a $7 billion market by 2015.

Galectin Therapeutics is best positioned with a human trial in cancer immunotherapy using a demonstrated safe drug. 2012 Galectin Therapeutics OTC:GALT 24 Science of Galectins Galectin Function Galectin Inhibitors Liver Fibrosis Mechanism of Action Regulatory and Clinical Plan Competitive Positioning Immune Enhancement in Cancer Therapy Mechanism of Action Regulatory and Clinical Plan Competitive Positioning 2012 Galectin Therapeutics OTC:GALT 25 SUMMARY Novel Mechanism Compounds First in class, proprietary compounds that inhibit galectin proteins.

If ipilimumab (Yervoy, BMS) is included, market is even larger. Blocking the Galectin Effect would be synergistic with all types of tumor vaccines or immune stimulatory approaches. In this regard, competition will come from other galectin blockers. While there are several companies exploring galectin inhibitors, they are early in development or have disadvantages related to our drugs.

Pierre van der Bruggen of the Ludwig Institute in Brussels, Belgium in collaboration with Galectin Therapeutics Cytokines (e.g., INF) Kill tumor cells Galectin 3 GM CT 01 Tumor Infiltrating Cytotoxic T Cells Tumor Cells Melanoma Proof of Concept Clinical Trial Design 2012 Galectin Therapeutics OTC:GALT 22 Phase I/II study of peptide vaccination associated with GM CT 01 in patients with advanced metastatic melanoma IMPD approved by EMA Group 2 patients have additional injection of GM CT 01 in cutaneous tumors Tumor Immune Enhancement Development Program 2012 Galectin Therapeutics OTC:GALT 23 2012 2013 2014 Preclinical Efficacy Studies GM CT 01 Phase I/II Melanoma Trial Top line results in Stage 1 Top line results in Stage 2 Efficacy in immune competent mice with syngeneic tumors Pursue Partnering Discussions Q1 Q2 Q4 Q1 Q3 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Competitive Positioning In Tumor Immunotherapy Market for tumor vaccines is expected to grow to $7B by 2015.

Pierre van der Bruggen of the Ludwig Institute in Brussels, Belgium in collaboration with Galectin Therapeutics Cytokines (e.g., INF) Kill tumor cells Galectin 3 Tumor Infiltrating Cytotoxic T Cells Tumor Cells GM CT 01 Blocks the Galectins Effect and the Restores the Ability of Tumor Infiltrating T Cells to Kill Tumor Cells 2012 Galectin Therapeutics OTC:GALT 21 Experiments performed by Dr.

Pierre van der Bruggen of the Ludwig Institute in Brussels, Belgium in collaboration with Galectin Therapeutics Cytokines (e.g., INF) Kill tumor cells Tumor Infiltrating Cytotoxic T Cells (CD8+ T Cells) Tumor Cells Galectins Effect : Tumors Inactivate Tumor Infiltrating T Cells Through Secretion of Galectin 3 Which Coats Surface of T Cells and Alters Receptor Function 2012 Galectin Therapeutics OTC:GALT 20 Experiments performed by Dr.

Ji yao Wang of Fudan University, Shanghai, China Liver Fibrosis, induced by injection of chemical toxin for 8 weeks Regression of Fibrosis after 4 weeks of treatment with GR MD 02 GR MD 02 Prevents and Completely Reverses Fibrosis in Non Alcoholic Steatohepatitis (NASH) 2012 Galectin Therapeutics OTC:GALT 13 normal mouse 0.33 GR MD 02 also reduces fat, liver cell death, and inflammation Early Rx Late Rx 2012 Galectin Therapeutics OTC:GALT 14 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2012 2013 2014 Post Transplant Fibrosis Phase II Post Tx Fibrosis Trial Phase I DE NASH NASH Fibrosis Development Program: GR MD 02 Phase II NASH with Fibrosis Trial Plan to File Fast Track Designation Plan to File Orphan Disease Status Plan to File Fast Track Designation Pre Clinical (Target SQ) Top line results Top line results Top line results Competitive Positioning in NASH 2012 Galectin Therapeutics OTC:GALT 15 General Mechanism Examples Comments Treat Diabetes and Insulin Resistance Pioglitazone Failed to achieve significant endpoints in phase II and phase III clinical trials Inhibit Lipid Metabolism Aramchol Colesevelam Cholesterol inhibition, no clinical results; weak mechanism Intestinal bile salt binder, no clinical results, weak mechanism Modulate the Immune System EGS21 (Enzo) Pentoxifylline Abandoned after phase II trial Non significant phase III results Protease Inhibition GS 9450 (Gilead) Liver Tox: abandoned (caspase inhibitor) Anti Oxidant MND 21 (Mochida) Cysteamine (Raptor) Omega 3 fatty acid (phase II trial) Increase glutathione in liver cells (phase II) GR MD 02: Most attractive mechanism: multiple sites of action in disease Independent of glucose or lipid metabolism Reverses established fibrosis Strong safety profile: Little chance of toxicity Science of Galectins Galectin Function Galectin Inhibitors Liver Fibrosis Mechanism of Action Regulatory and Clinical Plan Competitive Positioning Immune Enhancement in Cancer Therapy Mechanism of Action Regulatory and Clinical Plan Competitive Positioning 2012 Galectin Therapeutics OTC:GALT 16 The Vast Majority of Cancers Secrete Large Amounts of Galectins Which Have Multiple Roles in Tumor Pathogenesis Tumor cell invasion: extracellular matrix adhesion detachment Stromal cell function Metastasis: cell invasion and migration Angiogenesis Tumor immunity has recently been shown to be critically affected by galectins 2012 Galectin Therapeutics OTC:GALT 17 GM CT 01 Has Proven Safe in Over 100 Human Subjects and Has Been Shown to Have Effect In Colorectal Cancer Cancer Trial (DAVFU 003) Day 0 Day 28 GM CT 01 Chemo (5 FU) Phase II trial of 5 FU plus GM CT 01 in line 3/4 therapy of metastatic colorectal cancer 6.7 months median survival and reduced 5 FU related side effects In similar patients, Erbitux had a 6.1 month survival compared to 4.6 months with no therapy FDA confirmed that preclinical and clinical data are adequate to proceed with large clinical trials Deferring clinical trials in colorectal cancer to explore new exciting role for galectin inhibitors in cancer immunotherapy 2012 Galectin Therapeutics OTC:GALT 18 Tumor Infiltrating T Cells Are Able to Recognize and Kill Tumor Cells 2012 Galectin Therapeutics OTC:GALT 19 Experiments performed by Dr.

Fibrosis due to toxin exposure or fatty liver DOES NOT occur in mice that lack the galectin 3 gene . Galectin inhibitors block production of fibrogenic markers in the key human cell (stellate cells) responsible for liver fibrosis Galectin inhibitors reverse experimental fibrosis in rats induced by both fibrosis and fatty liver 2012 Galectin Therapeutics OTC:GALT 11 Key Evidence: Key Evidence: Galectin Inhibitor GR MD 02 Effectively Treats Toxin Induced Liver Fibrosis in Rats 2012 Galectin Therapeutics OTC:GALT 12 Galectin Therapeutics Data: Study performed under contract by Dr.

Inflammation 2. Fibrosis 3. Cancer Galectin 3 is key galectin in pathological processes Secreted Galectin Proteins Bind to cell surface and matrix glycoproteins ( galactose residues) Modulate cell signaling Promote cell cell interactions Promote cell matrix interactions Galectin Proteins Galectin Inhibitor Galectin Inhibitors: A New Class of Pathology Modulators 2012 Galectin Therapeutics OTC:GALT 9 Novel complex carbohydrate drugs that target secreted and membrane associated galectins by virtue of high molecular weight Strongest binding to galectin 3, most prominent galectin in disease processes Binding to galectins disrupts function and modulates multiple cellular pathways in pathology representing a new class of therapeutic agents Low toxicity potential as a carbohydrate with no toxic metabolites Two classes of compounds under development GM CT GR MD Low manufacturing costs; abundant natural plant product starting materials Strong patent position; developed in house; no encumbrances Science of Galectins Galectin Function Galectin Inhibitors Liver Fibrosis Mechanism of Action Regulatory and Clinical Plan Competitive Positioning Immune Enhancement in Cancer Therapy Mechanism of Action Regulatory and Clinical Plan Competitive Positioning 2012 Galectin Therapeutics OTC:GALT 10 Galectin 3 Is A Critical Target For Therapy of Liver Fibrosis Galectin 3 is produced in large amounts by fibrotic liver (animal and human) Galectin 3 is essential in mice for the development of liver fibrosis.

May be effective with unaltered immune system While tumor vaccines are patient and tumor specific, reversal of the Galectin Effect is universal The tumor vaccine market is forecast to be over $7 billion by 2015 2012 Galectin Therapeutics OTC:GALT 6 Science of Galectins Galectin Function Galectin Inhibitors Liver Fibrosis Mechanism of Action Regulatory and Clinical Plan Competitive Positioning Immune Enhancement in Cancer Therapy Mechanism of Action Regulatory and Clinical Plan Competitive Positioning 2012 Galectin Therapeutics OTC:GALT 7 Galectin Proteins Are Critical Participants In Pathogenesis of Many Fibrotic and Neoplastic Diseases 2012 Galectin Therapeutics OTC:GALT 8 PROMOTE PATHOLOGY Markedly Increased in: 1.

Regis Tech., Decode, Zafgen, Boston College, Tokai Pharma, MIT, University of Dortmund, Harvard University NASH and Liver Fibrosis are Multi Billion Dollar Markets In US Alone Transplants (6,291*) Wait List (17,000**) Death From Cirrhosis (44,677 # ) Cirrhosis (400,000 ## ) NASH: 9 15 Million * Performed in US in 2010 (UNOS) * * Prevalence in US 2010 (UNOS) The ONLY current therapy for advanced fibrosis (cirrhosis) is liver transplantation No approved medical therapy for fibrosis While there are treatments for some underlying etiologies (Hepatitis C and B), there is no approved therapy for NASH 2012 Galectin Therapeutics OTC:GALT 5 # Deaths in 1998 (AASLD Workshop, 2001) ## Prevalence in US 1976 1980 (NIDDK) Hepatitis C, Hepatitis B, Alcohol Prevalence in US 2011 (NIH) Immune Enhancement is Synergistic With Many Emerging Cancer Immunotherapies Enhancing the ability of the immune system to recognize and kill tumor cells is a very active area in the personalized approach to cancer therapy Two agents have been approved for use to date Dendritic cell vaccine: Provenge (Dendreon) T cell activator (CTLA4 receptor mAb): Ipilimumab (Yervoy, BMS) Many more vaccines and activators in development Our drugs reverse the Galectin Effect by which tumors inhibit the immune system and will be synergistic with all tumor immunotherapies.

Koor Biotechnologies, Charm Sciences, Glycogenesis, HU Medical School (Jerusalem), Harvard University Anthony Squeglia, MBA CFO Over 25 years in finance, strategic planning, marketing investor relations with technology companies ITT, ATT, Ascom Timeplex, Quentra Networks. BBA from The Wharton School, University of Pennsylvania; MBA from Pepperdine University Maureen Foley COO Over 30 years experience in business and operations management for public and private scientific, and biotech corporations and startup companies eHealthDirect, Signatron, ArsDigita and Thermo Fibergen Elena Chekhova, PhD Program Manager Over10 years of experience working in the biotech and life sciences industries, project management, manufacturing and business development.

Traber, MD President, CEO, CMO Over 25 years experience in biomedicine and pharmaceutical industries in research and development, clinical medicine, management and leadership, and business development. Medical expertise in liver disease GlaxoSmithKline, University of Pennsylvania, Baylor College of Medicine Anatole Klyosov, PhD Chief Scientist Over 35 years experience in biochemical reactions and their mechanisms, biotechnology, and carbohydrate research Moscow University, Russian Academy of Sciences, Harvard Medical School Eliezer Zomer, PhD EVP, Product Development Over 30 years experience in biotechnology engineering and regulatory in pharmaceuticals and diagnostics.

We cannot assure that we have identified all risks or that others may emerge which we do not anticipate. You should not place undue reliance on forward looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward looking statements. 2012 Galectin Therapeutics OTC:GALT 2 HIGHLIGHTS Proprietary Compounds First in class, proprietary compounds that inhibit galectin proteins Novel class of safe, complex carbohydrate drugs GR MD 02: Non alcoholic steatohepatitis (NASH) and other causes of liver fibrosis (clinical Q1 2013) GM CT 01: Enhance immune cell killing of cancer cells (Phase I/II) Validated Science Pre clinical models demonstrate that galectins are critical targets for intended diseases and mechanisms that would be novel in the market Large Market Opportunities NASH and liver fibrosis indications would be first therapies for completely unmet medical needs, representing a multi billion dollar market Enhanced immune killing of cancer cells is synergistic with many current and experimental therapies, expected to be a $7 billion market by 2015 Intellectual Property Control 100% of commercial rights GR MD 02: Matter and Methods pending (priorities of 2006 2011) GM CT 01: Matter and Methods granted (expire 2023, priority 2003) Experienced Management Team Management team has collective experience in multiple biotechnology and large Pharma companies and relevant scientific areas 2012 Galectin Therapeutics OTC:GALT 3 Experienced Management Team 2012 Galectin Therapeutics OTC:GALT 4 Peter G.

They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence on strategic partnerships, product competition, and others stated in risk factors contained in our SEC filings.

Corporate Summary February 2012 OTC: GALT Exhibit 99.1 Forward Looking Statements This presentation contains, in addition to historical information, forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as may, estimate, could, expect and others.

Strong Board with experience in large and entrepreneurial companies and pharma/biotechnology. James Czirr, Executive Chair. 2012 Galectin Therapeutics OTC:GALT 26